ORINY Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 21:49):

Stats
Tagesvolumen	21.00
Durchschnittsvolumen	164.00
Marktkapitalisierung	5.46B
EPS	$0 ( 2024-04-25 )
Nächstes Ertragsdatum	( $0 ) 2024-07-15
Last Dividend	$0.870 ( 2023-03-23 )
Next Dividend	$0 ( N/A )
P/E	21.08
ATR14	$0 (0.00%)

Orion Oyj Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Orion Oyj Finanzdaten

Annual	2023
Umsatz:	$1.19B
Bruttogewinn:	$640.60M (53.77 %)
EPS:	$1.550

FY	2023
Umsatz:	$1.19B
Bruttogewinn:	$640.60M (53.77 %)
EPS:	$1.550

FY	2022
Umsatz:	$1.34B
Bruttogewinn:	$849.00M (63.33 %)
EPS:	$2.49

FY	2021
Umsatz:	$1.04B
Bruttogewinn:	$593.50M (57.01 %)
EPS:	$0.690

Financial Reports:

No articles found.

Orion Oyj Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0.870 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Orion Oyj Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.69 - Stable (13.86%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.739	2016-03-22
Last Dividend	$0.870	2023-03-23
Next Dividend	$0	N/A
Payout Date	2023-04-17
Next Payout Date	N/A
# dividends	9	--
Total Paid Out	$7.52	--
Avg. Dividend % Per Year	0.00%	--
Score	3.36	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.69
Div. Directional Score	9.24	--

Next Divdend (Est)
(2024-10-07)

$0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

3.36

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SCGLY	Ex Dividend Junior	2023-05-25	Annually	0.00%
FIDS	Ex Dividend Junior	2023-05-18	Annually	0.00%
MHGU	Ex Dividend Junior	2023-09-14	Semi-Annually	0.00%
CLCGY	Ex Dividend Junior	2023-06-29	Annually	0.00%
STWRY	Ex Dividend Junior	2023-05-19	Annually	0.00%
HCMLY	Ex Dividend Knight	2023-05-09	Annually	0.00%
AILLM	Ex Dividend Knight	2023-07-14	Quarterly	0.00%
NWYF	Ex Dividend Junior	2023-08-04	Semi-Annually	0.00%
CRRFY	Ex Dividend Junior	2023-06-06	Sporadic	0.00%
TSGTY	Ex Dividend Knight	2023-06-23	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.178	1.500	6.45	9.67	[0 - 0.5]
returnOnAssetsTTM	0.148	1.200	5.05	6.06	[0 - 0.3]
returnOnEquityTTM	0.270	1.500	8.11	10.00	[0.1 - 1]
payoutRatioTTM	0.190	-1.000	8.10	-8.10	[0 - 1]
currentRatioTTM	1.782	0.800	6.09	4.87	[1 - 3]
quickRatioTTM	1.002	0.800	8.81	7.05	[0.8 - 2.5]
cashRatioTTM	0.396	1.500	8.91	10.00	[0.2 - 2]
debtRatioTTM	0.133	-1.500	7.78	-10.00	[0 - 0.6]
interestCoverageTTM	62.84	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	1.603	2.00	9.47	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.999	2.00	9.50	10.00	[0 - 20]
debtEquityRatioTTM	0.275	-1.500	8.90	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.551	1.000	4.15	4.15	[0.2 - 0.8]
operatingProfitMarginTTM	0.196	1.000	8.09	8.09	[0.1 - 0.6]
cashFlowToDebtRatioTTM	1.156	1.000	4.69	4.69	[0.2 - 2]
assetTurnoverTTM	0.835	0.800	7.76	6.21	[0.5 - 2]
Total Score				12.79

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.53	1.000	9.04	0	[1 - 100]
returnOnEquityTTM	0.270	2.50	8.78	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.999	2.00	9.67	10.00	[0 - 30]
dividendYielPercentageTTM	2.92	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.603	2.00	9.47	10.00	[0 - 30]
payoutRatioTTM	0.190	1.500	8.10	-8.10	[0 - 1]
pegRatioTTM	-8.39	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.184	1.000	7.89	0	[0.1 - 0.5]
Total Score				5.69

Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.